Completed PHASE3 INTERVENTIONAL 2-arm NCT02395172

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet

Sponsor: EMD Serono Research & Development Institute, Inc.

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Avelumab Docetaxel

Updated 20 times since 2017 Last updated: Jul 20, 2020 Started: Mar 24, 2015 Primary completion: Nov 22, 2017 Completion: Dec 3, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02395172, this PHASE3 trial focuses on Carcinoma, Non-Small-Cell Lung and remains completed. Sponsored by EMD Serono Research & Development Institute, Inc., it has been updated 20 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

20 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3
Nov 2025 — Dec 2025 [monthly]

Completed PHASE3
Oct 2025 — Nov 2025 [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3

▶ Show 15 earlier versions

Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3
Jan 2020 — Sep 2020 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Nov 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE3
Aug 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3
Jan 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE3
Aug 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Completed → Active Not Recruiting
Dec 2017 — Feb 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Oct 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
Sep 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Data source: EMD Serono

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Alba Iulia, Romania , Alicante, Spain , Anaheim, United States , Angers, France , Ankara, Turkey (Türkiye) , Arequipa, Peru , Athens, United States , Badalona, Spain , Bahía Blanca, Argentina and 199 more locations